Two patients with the same diagnosis could have tumors that behave in completely different ways and respond to treatment differently. Cancer care is becoming more and more personalized based on genetic results. Modern oncology is shifting from treating where cancer lives to treating what drives it at the molecular level.
Genetic and genomic testing has made this shift possible by identifying the specific mutations actually powering a tumor’s growth. This helps your care team curate a treatment plan that identifies what therapies are most likely to work and when.
How genomic medicine powers personalized treatment
Understanding how personalized medicine improves cancer treatment starts with a fundamental distinction: not all mutations are created equal.
Germline mutations are inherited, present in every cell from birth, and passed down through families. Somatic or genomic mutations, by contrast, are acquired during a person’s lifetime, triggered by factors like UV exposure, carcinogens, or simple cellular aging. Most solid tumors are driven by somatic mutations, and identifying exactly which ones are at work is where modern genomic sequencing becomes indispensable.
Through techniques like next-generation sequencing (NGS), oncologists can now scan thousands of genes simultaneously to pinpoint the specific molecular “drivers” accelerating a tumor’s growth. Next-generation sequencing research confirms that this level of resolution is fundamentally reshaping treatment decisions.
How it works: From sequencing to treatment plan:
- Tumor tissue or liquid biopsy sample is collected
- NGS analyzes hundreds of cancer-relevant genes simultaneously
- Identified driver mutations are cross-referenced against known targeted therapies
- A molecular tumor board reviews findings to build a customized regimen
The results can be striking. In the I-PREDICT trial, molecular profiling generated 157 different treatment regimens across just 210 patients, with nearly 95% carrying unique tumor DNA profiles, highlighting how individualized and unique human biology can be.
How biomarkers like HER2 are changing treatment options
One of the clearest real-world examples of precision oncology is the HER2 biomarker. HER2 (human epidermal growth factor receptor 2) is a protein that can be overexpressed or amplified in certain cancers, including breast, gastric, and some lung cancers. When HER2 is present at high levels, it acts like a growth accelerator, signaling cancer cells to divide and spread more aggressively.
In the past, patients with HER2-positive cancers often had fewer targeted options and were treated primarily with standard chemotherapy. Today, testing for HER2 status is a routine part of diagnosis because it directly changes the treatment plan.
If a tumor is HER2-positive, it may respond to HER2-targeted therapies designed specifically to block this pathway. These treatments work by either blocking the HER2 signal, marking cancer cells for immune destruction, or delivering chemotherapy directly into HER2-expressing cells.
If a tumor is HER2-negative, those therapies typically aren’t effective, and the care team instead focuses on other molecular drivers or treatment approaches. In this way, a single biomarker test can fundamentally redirect the entire treatment strategy, sparing patients from less effective therapies and guiding them toward options that are far more likely to work.
This is the core promise of biomarker-driven oncology: two patients with the same cancer type may receive completely different treatments based on the biology of their tumor rather than its location alone.
From research to routine: Bridging the gap
Despite major advances in precision oncology, significant gaps in biomarker testing continue to limit patients’ access to the most effective, personalized treatments. Experts emphasize that while the science and technology for genomic and biomarker testing are well established, health care systems, including payer policies, infrastructure, and care coordination, haven’t kept pace. In some cases, testing that could guide better treatment decisions is delayed or even denied by insurers who may not recognize its long-term value, creating barriers at the point of care.
These gaps are further compounded by inconsistent adoption in clinical practice, leaving many patients without guideline-recommended testing or timely results needed to inform treatment decisions. Ultimately, the disconnect between innovation and implementation means that many patients miss opportunities for targeted therapies, highlighting the urgent need for better system-level alignment, education, and access to ensure biomarker-driven care reaches everyone who could benefit.
This is why staying informed about the latest advances and proactively asking your care team about genetic and biomarker testing can be an important step in ensuring you are aware of all potential treatment options.
How to get your personalized treatment plan
If you’re not sure if you’ve received biomarker testing, below are the steps on how you can get started.
- Ask your care team about biomarker testing. Ask directly if genetic testing is appropriate for your cancer type and stage. Don’t wait for your provider to bring it up first; advocate for it proactively.
- Understand the difference between liquid and tissue biopsies. A tissue biopsy analyzes tumor cells directly from a sample, while a liquid biopsy detects tumor DNA circulating in your blood. Ask your care team which method is most appropriate given your diagnosis, as each has specific advantages depending on tumor location and accessibility.
- Discuss actionable mutations with a genetic counselor. Not every genetic variant identified by sequencing will change your treatment plan. A genetic counselor can help you distinguish which mutations are actionable, meaning they can be targeted by existing therapies, and which require monitoring or further research.
- Explore all your options, including clinical trials. Certain clinical trials only accept patients with specific mutations, and knowing your biomarker status allows you to uncover all of your treatment options.
Talk openly with your care team, track how you’re feeling between appointments, and lean on trustworthy resources like Outcomes4Me to stay empowered.
